Vaxart to Present at the Mucosal Immunology Conference in Berlin on July 17, 2015

SOUTH SAN FRANCISCO, Calif.--()--Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Vaxart Founder and Chief Scientific Officer Dr. Sean Tucker, PhD, will present clinical data from its seasonal flu vaccine program at the upcoming Society for Mucosal Immunology Conference in Berlin.

Dr. Tucker will present the data in his presentation “Mucosal Immune Responses Following Radio Controlled Capsule Delivery to Human Intestines: An Open Label Clinical Trial of an Influenza Vaccine Based on Recombinant Adenovirus” on Friday, July 17, 2015.

About Vaxart

Vaxart is a privately held, clinical-stage company developing a broad range of vaccines based on its proprietary oral recombinant vaccines platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and eliminate medical waste and risk of injury associated with injectable vaccines. For more information, please visit www.vaxart.com.

Contacts

WCG
Katie Hogan, 415-658-9745
khogan@wcgworld.com

Release Summary

Vaxart announced that Founder and CSO Dr. Sean Tucker, PhD, will present clinical data from its seasonal flu vaccine program at the Mucosal Immunology Conference in Berlin on July 17, 2015.

Contacts

WCG
Katie Hogan, 415-658-9745
khogan@wcgworld.com